Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 20091634 | Other Identifier | Office of Research Administration |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall objective will be to evaluate clinical predictors of outcomes in patients who undergo endovenous sclerotherapy for the treatment of varicose veins.
A prospective cohort study of patients who undergo endovenous sclerotherapy over 2 years. There are no deviations in usual clinical assessment and care of patients seeking varicose vein treatment. The purpose of this protocol is only to collect clinical and biomarker information related to this standard treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Endovenous Sclerotherapy | For those who have been diagnosed with varicose veins of the leg and have been scheduled to undergo an endovenous sclerotherapy procedure |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of obliteratin (total or partial) of injected varicosity. | assessment will be at 1, 12, and 26 weeks. | |
| Improvement in venous stasis symptoms. | assessment will be at 1, 12, and 26 weeks | |
| Change in quality of life. | assessment will be at 1, 12, and 26 weeks | |
| Associations between clinical outcomes and biomarkers. | assessment will be at 1, 12, and 26 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrence of varicosities. | assessment will be at 1, 12, and 26 weeks | |
| Adverse events reported following procedure. | assessment will be at 1, 12, and 26 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Vascular or primary care clinic patients who have been scheduled to undergo an endovenous sclerotherapy procedure
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Suman W. Rathbun, M.D. | Oklahoma University Health Sciences Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Oklahoma Health Sciences Center campus at the OU Vascular Center | Oklahoma City | Oklahoma | 73104 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014648 | Varicose Veins |
| D020246 | Venous Thrombosis |
| D014456 | Ulcer |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
Not provided
Not provided
Not provided
Not provided
Not provided
blood samples will be obtained for measurement of D-dimer, fibrin monomer, and total microparticles.
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |